Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at UEG Week 2026
Palisade Bio Inc PALI
$1.45
▼ -3.33%
($-0.05)
Open
$1.54
Prev Close
$1.50
Day Range
$1.42 – $1.55
52W Range
$0.79 – $2.86
Market Cap
$252.69M
Beta
1.52
EPS (TTM)
$-0.64
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2006-12-20 |
| Shares Out. | 173,580,000 |
| Website | palisadebio.com/ ↗ |
| Phone | 13026974590 |
| Employees | 14 |
| Revenue | $500,000 |
| Gross Profit | $500,000 |
| Net Income | -$10.6M |
| Free Cash Flow | -$18.2M |
| Total Assets | $127.3M |
| Total Liabilities | $5.6M |
| Equity | $121.7M |
About Palisade Bio Inc
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
Palisade Bio Inc is a publicly traded company under the ticker symbol PALI on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
16 analysts (2026-09-01)
📰 Latest News for PALI
Palisade Bio To Present Four Presentations At United European Gastroenterology Week 2026 For Its PALI-2018 Program
Palisade Bio Advances PALI-2108 Into Phase II for Ulcerative Colitis and Crohn’s
Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance
Palisade Bio Receives Health Canada's Clearance For Its Clinical Trial Application For ASCENTRA-UC Trial Of PALI-2108 To Treat Severely Active Ulcerative Colitis
HC Wainwright & Co. Reiterates Buy on Palisade Bio, Maintains $7 Price Target
Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn’s Disease, Expanding Phase 2 Development Across IBD
Palisade Bio Receives FDA Clearance For Its Investigational New Drug Application For PALI-2108 To Treat Crohn's Disease; First Participant Enrollment Anticipated In Q1 Next Year